drugset / Trial / NCT05081583

Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients

NCT05081583 ↗

Non-randomizedCrossoverOpen-labelBasic science

Summary

Supplements containing goldenseal, a perennial herb native to North America, have consistently ranked among the top 20 highest selling natural products throughout the last decade. Goldenseal products are marketed as licensed natural health products in Canada and as dietary supplements in the United States. Natural products made from dried roots of the goldenseal plant are purported to have therapeutic value and are used to self-treat a range of medical complications, including the common cold, allergic rhinitis, and digestive disorders, such as diarrhea and constipation. Based on a previous clinical study, goldenseal have been shown to precipitate pharmacokinetic interactions with metformin in healthy volunteers. This follow-up study aims to evaluate the goldenseal-metformin interaction in type 2 diabetic patients. Results from this proposed clinical study will (1) characterize the pharmacokinetic interaction between the botanical dietary supplement goldenseal and anti-diabetic drug metformin, (2) provide evidence-based recommendations to mitigate drug interaction risks, and (3) contribute to the development of a comprehensive strategy for effectively assessing other potential natural-product drug interactions.

Timeline

Start
2021-09-16
Primary completion
2023-01-16
Completion
2023-08-31

Outcome

Met primary endpoint

paper of 0.93 [0.86-1.01] laying within the predefined no-effect range (0.80-1.25). PMID 39943692 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Hcl 1Mg/Ml Inj Unknown 0.5 mg Intravenous